Pharma Harvest From Phase 1 Deal May Be Transshipments — Panjiva
MENU

Panjiva_research_logo

Pharma Harvest From Phase 1 Deal May Be Transshipments

China 2205 Health Care 145 Trade Deals 806 U.S. 3973

There has been a surge in interest from global pharmaceutical companies in China’s single buyer program. The program, which sources generic drugs, has seen a 53% year over year drop in offered prices. It may provide a vehicle for China to meet part of its purchasing commitments made to the U.S. under the phase 1 trade deal. U.S. pharma exports to China reached $4.1 billion in the 12 months to Nov. 30 after rising 49.2% year over year. That growth would need to accelerate to 63.2% for each of 2020 and 2021 for pharma to contribute its proportionate share of China’s commitment to raise its...

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2020 S&P Global. All Rights Reserved.